All In Biotech

Drug Trial Radar · NCT03906799

Study on OMT-28 in Maintenance of Sinus Rhythm in Patients With Persistent Atrial Fibrillation (AF)

A Placebo-controlled, Double-blind, Randomized, Dose-finding Phase II Study on OMT-28 in MaIntenance of Sinus Rhythm After Electrical Cardioversion in Patients With Persistent Atrial Fibrillation (PROMISE-AF)

Last checked: Nov 19, 2026Latest source record: Sep 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 136 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

136

Actual

Start

Mar 19, 2019

Primary completion

Nov 20, 2019

Study completion Mar 20, 2020

Sponsor

Lead sponsor
Omeicos Therapeutics GmbHIndustry
Sponsor type
Industry
First posted
Apr 8, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, dose-finding, placebo-controlled, parallel group, multicenter, phase II study to evaluate the efficacy, safety, and popPK of three different doses of OMT-28 given once daily versus placebo in patients with persistent AF.

Conditions

  • Atrial Fibrillation

Interventions

  • OMT-28Drug

    1 capsule given daily orally from Visit 3 (Day 1) to Visit 8 (Day 99 ± 3 days).

  • PlaceboDrug

    1 capsule given daily orally from Visit 3 (Day 1) to Visit 8 (Day 99 ± 3 days).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assessment of AF Burden After OMT-28 AdministrationTime frame: Up to 4.5 months

Locations

25 sites in 4 countries. Site status is shown where the registry gives one.

  • Site 401

    Sofia, Bulgaria

  • Site 404

    Stara Zagora, Bulgaria

  • Site 402

    Varna, Bulgaria

  • Site 301

    Kolín, Czechia

  • Site 303

    Pilsen, Czechia

  • Site 302

    Slaný, Czechia

  • Site 205

    Budapest, Hungary

  • Site 201

    Budapest, Hungary

  • Site 203

    Debrecen, Hungary

  • Site 206

    Hódmezővásárhely, Hungary

  • Site 202

    Pécs, Hungary

  • Site 204

    Zalaegerszeg, Hungary

  • Site 102

    Cherkasy, Ukraine

  • Site 110

    Ivano-Frankivsk, Ukraine

  • Site 104

    Kharkiv, Ukraine

  • Site 107

    Kharkiv, Ukraine

  • Site 108

    Khmelnytskyi, Ukraine

  • Site 113

    Kiev, Ukraine

  • Site 106

    Kiev, Ukraine

  • Site 101

    Kiev, Ukraine

  • Site 109

    Kiev, Ukraine

  • Site 112

    Kiev, Ukraine

  • Site 105

    Odesa, Ukraine

  • Site 103

    Uzhhorod, Ukraine

  • Site 111

    Zhytomyr, Ukraine

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.